Publication
Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor [...]
Podcast
[av_textblock size='' av-medium-font-size='' av-small-font-size='' av-mini-font-size='' font_color='' color='' av-desktop-hide='' av-medium-hide='' av-small-hide='' [...]
Media Coverage
Piramal Pharma Solutions and Bolt Biotherapeutics Sign Production Agreement ADC [...]
Media Coverage
U.S. Patent for Bolt Biotherapeutics’ Boltbody™ ISAC Platform Technology is [...]
Media Coverage
Randall Schatzman, Ph.D. to Lead Growth of Immune- Stimulating Antibody [...]
Media Coverage
How the Next Generation Antibody Drug Conjugates Expands Beyond Cytotoxic [...]
Media Coverage
Bolt Biotherapeutics Nabs $93.5M to Push Provenge Inventor's New Idea [...]
Media Coverage
Bolt’s Myeloid Twist on ADCs Charged up with $93.5M series [...]
Media Coverage
Pfizer-Backed Bolt Therapeutics Strikes $93.5M Funding Round As Lead Med [...]
Media Coverage
Agonist ecstasy? HER2 (and more) ‘Bolt’-on strategy draws $93.5M series [...]